Sanuwave Health (NASDAQ:SNWV) Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Sanuwave Health (NASDAQ:SNWVFree Report) from a hold rating to a buy rating in a research report released on Friday morning.

SNWV has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sanuwave Health in a research note on Saturday, September 27th. Northland Securities began coverage on shares of Sanuwave Health in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $55.00 price objective for the company. Roth Capital upped their target price on Sanuwave Health from $54.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, August 22nd. Finally, Northland Capmk upgraded Sanuwave Health to a “strong-buy” rating in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sanuwave Health has an average rating of “Moderate Buy” and a consensus target price of $55.00.

View Our Latest Stock Report on Sanuwave Health

Sanuwave Health Stock Performance

NASDAQ SNWV opened at $37.43 on Friday. The business’s 50 day moving average price is $37.73 and its 200-day moving average price is $33.87. Sanuwave Health has a fifty-two week low of $5.63 and a fifty-two week high of $46.58. The company has a market cap of $320.70 million, a P/E ratio of -4.54 and a beta of 1.33.

Sanuwave Health (NASDAQ:SNWVGet Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.10. The firm had revenue of $10.16 million for the quarter, compared to analysts’ expectations of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Trading of Sanuwave Health

Institutional investors have recently modified their holdings of the company. Solas Capital Management LLC purchased a new position in shares of Sanuwave Health in the 1st quarter worth approximately $20,658,000. AWM Investment Company Inc. acquired a new stake in Sanuwave Health in the first quarter valued at approximately $18,153,000. Geode Capital Management LLC purchased a new position in Sanuwave Health in the second quarter worth $5,184,000. Stonebridge Wealth Management LLC purchased a new position in Sanuwave Health in the second quarter worth $1,696,000. Finally, Evernest Financial Advisors LLC acquired a new position in shares of Sanuwave Health during the second quarter worth $823,000. 42.53% of the stock is currently owned by institutional investors.

Sanuwave Health Company Profile

(Get Free Report)

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

Further Reading

Receive News & Ratings for Sanuwave Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanuwave Health and related companies with MarketBeat.com's FREE daily email newsletter.